Ligand Pharmaceuticals Inc.
3911 Sorrento Valley Boulevard
473 articles with Ligand Pharmaceuticals Inc.
At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated reviewed the recent progress of its business and financial growth outlook.
Ligand Pharmaceuticals Incorporated and Royalty Pharma announce the sale of Ligand’s Promacta®-related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for $827 million in cash.
Event to feature business updates and presentations by four corporate partners
Analyst day to be held on Tuesday March 12 at 10:00 a.m. Eastern Time in New York City
Ligand received an upfront payment and is eligible to receive development milestone payments and tiered royalties for each product incorporating an OmniAb-derived antibody.
Ligand Pharmaceuticals Incorporated announces closing an investment in Dianomi Therapeutics, Inc., a biopharmaceutical company focused on improving the delivery and efficacy of large and small molecules in the treatment of a variety of diseases and on therapies for inflammatory diseases, such as osteoarthritis and pain.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced that it has closed a reverse merger with Apricus Biosciences, Inc.
PTX-022 is a late-stage drug candidate targeting pachyonychia congenita
As the holidays approach, the U.S. Food and Drug Administration (FDA) is getting in a few drug approvals to wrap up the year. This week there are two decision dates, with another that has been delayed for several months. Here’s a look.
Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo
The research utilizes Vernalis' fragment and structure-based drug discovery platform for two undisclosed oncology targets.
Raises 2018 Financial Guidance
Ligand Pharmaceuticals Incorporated announces that the company is scheduled to participate in Stephens NY Investment Conference in New York City.
Ligand Pharmaceuticals Incorporated announced today plans to report third quarter 2018 financial results on November 8, 2018.
10/12/2018Apotheker Group, Search and Advisory, Executive Search & Advisory firm specializing in the life sciences industry, is pleased to announce its official launch. The launch was celebrated recently at the Electric Room lounge at the Dream Downtown Hotel in NYC on the 4th of October.
Ligand’s portfolio now includes more than 178 shots on goal
Apotheker Group Executive Search and Advisory Services Firm Celebrates its Launch and Honors Recently Appointed ACMA Board of Governors
Apotheker Group, Search and Advisory, an Executive Search & Advisory firm specializing in the life sciences industry, is hosting an invite-only event on Thursday, October 4th, 2018 at the Dream Downtown Hotel in Manhattan, NY to celebrate its recent launch as well as the newly appointed ACMA Board of Governors.
Ligand Pharmaceuticals Inc. announces that the company is scheduled to participate in H.C. Wainwright 20th Annual Global Investment Conference in New York City.
Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash
Ligand to gain broad portfolio of partnered and unpartnered programs, a self-funding R&D group and approximately $32 million of net cash
Updates 2018 Full Year Guidance
Rev. Fr. Emmanuel Lemelson Calls on Congress, Office of Inspector General to Investigate SEC Failures
Failure to prosecute Alleged Multi-Year Accounting and Securities Fraud at Ligand Pharmaceuticals (NASDAQ: LGND) Diminishes SEC Credibility, Warrants Investigation